The path to curing
Cardiovascular disease
Starts Here

We are harnessing the power of immunotherapy to develop and deliver innovative therapies that treat cardiovascular disease.

FOCUS ON Cardio-Immunology

Bitterroot Bio is committed to pioneering the emerging field of cardio-immunology, which investigates the interplay between the immune system and cardiovascular health. Through our research, we have uncovered the critical roles that immune cells and immune modulators play in the development and progression of cardiovascular disease. Our approach builds on the success of immunotherapies in oncology by harnessing the immune system’s natural ability to fight disease.

By understanding the intricate mechanisms by which these cells contribute to disease, we are developing innovative immunotherapies that target the root causes of cardiovascular disease rather than just treating its symptoms. Our approach is grounded in scientific research and close collaboration with cardiologists to ensure the safety and efficacy of our therapies for patients. Our ultimate goal is to provide new hope to those suffering from cardiovascular disease and transform the way these diseases are treated.

Atherosclerosis: AN INFLAMMATORY DISEASE

Atherosclerosis is a complex inflammatory disease that is characterized by the accumulation of fatty deposits, or “plaques,” in the walls of the arteries. Plaques are made up of cholesterol, lipids, and other substances that cause the arteries to narrow and harden, making it difficult for blood to flow through them.

Atherosclerotic plaque formation is a dynamic biological process perpetuated by inflammation. Inflammation in blood vessel plaque triggers an immune response. Immune cells and circulating factors called “cytokines” further increase inflammation and the buildup of dead, or necrotic, debris within the vessel wall. This vicious cycle of inflammation contributes to the evolution and further maturation of the atherosclerotic plaques.

Over time, some plaques may destabilize and rupture, triggering the formation of a clot within the lumen of an artery. These clots can suddenly block blood flow to healthy heart or brain tissue, leading to a cardiovascular event.

We believe that it is possible to prevent atherosclerotic plaques from progressing by targeting CD47, a widely expressed cellular receptor well known for its immunoregulatory functions. This bold and novel therapeutic approach is being investigated to reduce the incidence of debilitating heart attacks and stroke.

CD47 Illustration

THE ROLE OF CD47

CD47 is a protein that is expressed on the surface of cells and acts as a potent “don’t eat me” signal. Its presence enables harmful cells to avoid immune cells such as macrophages. By evading detection and destruction by the immune system, these harmful cells join a growing plaque within the arterial wall.

Recent research has shown that CD47 levels are elevated in the walls of blood vessels of patients with atherosclerosis and that this elevation is associated with an increased risk of heart attack and stroke. Further studies have revealed that blocking CD47 can enhance macrophage activity and reduce the formation of plaque.

The development of a novel safe and effective “anti-CD47” therapy opens the potential to slow or to prevent the formation of atherosclerotic plaques, with the promise of ultimately making a world without cardiovascular disease possible.

OUR TEAM: COFOUNDERS

Nick Leeper

Nick Leeper, MD

Chief of Vascular Medicine, Stanford University
Board Director
Irving Weissman

Irving L. Weissman, MD

Professor of Pathology, Stanford University Member, National Academy of Sciences
Board Director
John Martin

John C. Martin, PhD, MBA

Former Chairman and CEO, Gilead Sciences
In Memoriam
Lou Lange

Lou Lange, MD, PhD

General Partner, Asset Management Ventures Former Chairman & CEO, CV Therapeutics

OUR TEAM: Management

Stephen Hill
Interim CEO
Board Director
Sherwin Chen, MS, JD
Chief Legal Officer and Corporate Secretary
Charles Kaplan, PhD
SVP, Research
Will Krause, MAFM
SVP, Finance & Operations
Derek Klarin
Executive Director, Genomic Medicine & Data Science
Smital Shah, MS
Strategic Advisor

Board of Directors

Steve Gillis
Managing Director, ARCH Venture Partners
Executive Chairman of the Board
Andrew ElBardissi
Partner, Deerfield Management
Board Director
Irving Weissman
Professor of Pathology, Stanford
Member, National Academy of Sciences
Board Director
Nick Leeper
Chief of Vascular Medicine, Stanford University
Board Director
Stephen Hill
Interim CEO
Board Director
Anthony Philippakis
Venture Partner, GV
Chief Data Officer and Institute Scientist, Broad Institute
Board Observer

CLINICAL ADVISORY BOARD

Robert Harrington, MD

STEPHEN AND SUZANNE WEISS DEAN, WEILL CORNELL MEDICINE,
PROVOST FOR MEDICAL AFFAIRS
Cornell University

Marc Bonaca, MD, MPH

William R. Hiatt Endowed Chair in Cardiovascular Research
Executive Director, CPC Clinical Research
Affiliated with the University of Colorado School of Medicine

Paul Ridker, MD, MPH

Eugene Braunwald Professor of Medicine
Director of the Center for Cardiovascular Disease Prevention
Brigham & Women’s Hospital

Jonathan Weinsaft, MD

CHIEF OF THE DIVISION OF CARDIOLOGY
ANTONIO M. GOTTO JR., MD, PROFESSOR IN ATHEROSCLEROSIS AND LIPID RESEARCH/MEDICINE
Weill Cornell Medicine and New York Presbyterian/Weill Cornell Medical Center

Christie Ballantyne, MD

CHIEF OF THE SECTION OF CARDIOVASCULAR RESEARCH
J.S. ABERCROMBIE CHAIR OF ATHEROSCLEROSIS AND LIPOPROTEIN RESEARCH
DIRECTOR OF THE CENTER FOR CARDIOMETABOLIC DISEASE PREVENTION
Baylor College of Medicine

Daniel J Rader, MD

SEYMOUR GRAY PROFESSOR OF MOLECULAR MEDICINE, CHAIR, DEPARTMENT OF GENETICS
CHIEF, DIVISION OF TRANSLATIONAL MEDICINE AND HUMAN GENETICS
Perelman School of Medicine at University of Pennsylvania

Sandy Ferber Brine, MSc

Fmr. CEO/President, Array Biostatistics

Douglas Mann, MD

Ada L. Steininger Professor of Cardiology
Professor of Medicine, Cell Biology and Physiology
Washington University School of Medicine in St. Louis

SCIENTIFIC ADVISORY BOARD

Kathryn Moore, PhD

Jean and David Blechman Professor of Cardiology
Director of the Cardiovascular Research Center
NYU Grossman School of Medicine

Siddhartha Jaiswal, MD, PhD

Assistant Professor of Pathology
Stanford University

Klaus Ley, MD

Co-Director, Immunology Center of Georgia (IMMCG)
GRA Bradley Turner Eminent Scholar Chair in Immunology
Professor of Physiology
Medical College of Georgia, Augusta University
Immunology Center of Georgia

Matthias Nahrendorf, MD

Richard Moerschner Endowed Chair at the MGH Research Institute
Professor of Radiology
Director, Mouse Imaging Program
Massachusetts General Hospital

Kristy Red-Horse, PhD

Investigator, Howard Hughes Medical Institute
Associate Professor, Department of Biology
Stanford University

Filip K. Swirski, PhD

Director, Cardiovascular Research InstituteThe Arthur and Janet C. Ross Professor of Medicine, CardiologyProfessor, Diagnostic, Molecular and Interventional Radiology
Icahn School of Medicine at Mt. Sinai

Israel Charo, MD, PhD

Professor of Medicine, University of California San Francisco (Emeritus)

Recent News:

Company Updates

February 13, 2026

SELECTED PUBLICATIONS & MEDIA:

Anti-CD47 Therapy Early Macrophage-Specific Transcriptomic Changes

Anti-CD47 Therapy Early Macrophage-Specific Transcriptomic Changes

American Heart Association Annual Scientific Session – 2025
Derek Klarin, Hua Gao, Pierre Signore, Jey Jeyaseelan, Kevin Paavola, Eric Cheung, Rui Yun, Meng Zhang, Nicholas J. Leeper, Pavan Cheruvu, Craig T. Basson, and Charles Kaplan
Cardioprotection Rat Model Ischemic Injury

Cardioprotection Rat Model Ischemic Injury

American Heart Association Annual Scientific Session – 2025
Pierre E. Signore, Zhihua Wei, Kinya Seo, Eric Cheung, Meng Zhang, Kevin Paavola, Yasinee Rotratsirikun, Nicholas Leeper, Pavan Cheruvu, Craig T. Basson, Charles Kaplan
Accelerating Drug Translation

Accelerating Drug Translation: Role of Coronary Computed Tomography Angiography Plaque Imaging Candidates as Surrogate Biomarkers

Science Direct
Effect of CD47 Blockade on Vascular Inflammation

Effect of CD47 blockade on vascular inflammation

New England Journal of Medicine – 2021
Jarr KU, Nakamoto R, Doan BH, et al.
No more publications to show

TED Talk | Is There a Link Between Cancer and Heart Disease?

Biotech2050 | Bitterroot Bio’s Bold Vision with CEO Pavan Cheruvu

Why Bitterroot?

Inspired by our cofounders’ connections to Montana—home to the Bitterroot River and the bitterroot plant—our name has a multiplicity of meanings.

Bitterroot is…

CONFLUENCE

CONFLUENCE

Just as the East Fork and West Fork Bitterroot streams join to form a single, more powerful river, we seek to unite two arms of medical innovation, opening new channels through which we may rewrite the future of human health

Pressure and Flow

PRESSURE + FLOW

Like the path of a river, we will never stop evolving, adapting, or flowing. We find new ways to get it done because there is no other way

Elegance Icon

ELEGANCE

We have deep reverence for the vast and intricate circuit that is human vasculature. We seek to emulate nature’s elegance in our science

Tenacity

TENACITY

The bitterroot plant has the might to bring itself back to life from its own dry, dying roots. We are inspired by this tiny plant’s tenacious way of living and its ability to press on for the good of the planet

Truth Icon

THE BITTER TRUTH

We are authentic in our interactions, unapologetic in our efforts, undaunted by what lies ahead, and unrelenting in the science

Careers:

Interested in learning more about the Bitterroot team? We’d love to connect.

Fake Online Solicitations

The solicitations may include our trademarks and attachments asking the recipients to fill out questionnaires regarding employment history and other information to send back to the sender. These individuals may be looking to collect personal information about you for the purpose of perpetrating a fraud or stealing your identity.

All legitimate Bitterroot Bio job openings are posted on the Bitterroot Bio corporate site at www.brbio.com. If you have any questions or concerns about potential fraudulent employment opportunities or contact from someone supposedly representing Bitterroot Bio, please reach out to us at [email protected]

If you have provided personally identifiable information (such as social security number, bank numbers or credit card information) to an unauthorized party, please contact one of the following agencies to report this disclosure and receive guidance on any further actions you should take to protect your identity:

  • FTC toll free hotline: 877-FTC-HELP (877-382-4357)
  • FTC online complaint form (http://www.ftc.gov/)
  • Internet Fraud Complaint Center (http://www.ic3.gov/)
  • Non-emergency number for your local police department

Contact Us:


Bitterroot Bio is a privately held company dedicated to the pursuit of breakthroughs in cardiovascular medicine. We are committed to improving the lives of patients, and we believe that focusing on research and development is the best way to achieve that goal. We do not engage in, support, or advocate on behalf of political, social, environmental, or other causes that are unrelated to our mission.
Scroll to Top